Seelos Therapeutics (SEEL)
(Real Time Quote from BATS)
$0.20 USD
0.00 (0.45%)
Updated Sep 19, 2024 01:36 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SEEL 0.20 0.00(0.45%)
Will SEEL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SEEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SEEL
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
SEEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SEEL
Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Biotech Alert: Searches spiking for these stocks today
Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more
SEEL Stock Earnings: Seelos Therapeutics Beats Revenue for Q2 2024